Moneycontrol
Get App
Last Updated : Mar 11, 2014 07:10 PM IST | Source: CNBC-TV18

Health Min's compulsory license proposal hits DIPP hurdle

Compulsory licence is a tool through which developing countries like India can produce patented drugs, can allow companies to produce patented drugs in a much cheaper and affordable way.


Health ministry's proposal for a compulsory licence for anti-cancer drug Dasatinib has hit a hurdle. The Department of Industrial Policy and Promotion (DIPP) is not convinced about the proposals submitted by the ministry.


Compulsory licence is a tool through which developing countries like India can produce patented drugs, can allow companies to produce patented drugs in a much cheaper and affordable way.


Also Read: Dr Reddy's launches antibiotic drug in US market


Read more at: The health ministry for the past two years has been trying to obtain a compulsory licence for an anti-cancer drug, Dasatinib. It is used to treat leukemia and costs more than Rs 1.5 lakh per month for a Dasatinib therapy. The health ministry has been proposing that a compulsory licence notification should be issued by the DIPP so that Indian companies can produce that drug in a much more affordable way.


However, the DIPP is now saying that the kind of data and information provided by the health ministry is not enough to produce or grant a compulsory licence for Dasatinb. It has asked for more information from the health ministry because Section 92, which the health ministry is invoking, is untested clause in the Patents Act and does not wish that this compulsory licence should be challenged by Bristol-Myers Squibb which manufactures Dasatinib.

DIPP wants a watertight case as far as compulsory licence is concerned. Hence, it is waiting for more information from the health ministry before it makes up its mind regarding granting of a compulsory licence for manufacture of affordable Dasatinib in India.

First Published on Mar 11, 2014 07:10 pm
More From
Loading...
Sections
Follow us on
Available On
PCI DSS Compliant